The Role of Testosterone in the Metabolic Syndrome in Men

  • Farid Saad


The metabolic syndrome is a cluster of components which have been identified from many epidemiological studies as the most important risk factors for cardiovascular diseases and type 2 diabetes. Different definitions have slightly different cutoff levels, but all contain the same components:


Metabolic Syndrome Insulin Sensitivity Waist Circumference Androgen Deprivation Therapy GnRH Antagonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Basaria S. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth. J Androl. 2008;29(5):534–9.PubMedCrossRefGoogle Scholar
  2. Corona G, Forti G, Maggi M. Why can patients with erectile dysfunction be considered lucky? The association with testosterone deficiency and metabolic syndrome. Aging Male. 2008;11:193–9.PubMedCrossRefGoogle Scholar
  3. Haider A, Gooren L, Padungtod P, Saad F. Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men. Andrologia. 2009;41:7–13.PubMedCrossRefGoogle Scholar
  4. Heufelder A, Saad F, Bunck M, Gooren L. 52-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycaemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl. 2009;30:726–63. Epub 2009 Jul 3.PubMedCrossRefGoogle Scholar
  5. Pitteloud N, Hardin M, Dwyer A, Valassi E, Yialamas M, Elahi D, Hayes F. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab. 2005;90:2636–41.PubMedCrossRefGoogle Scholar
  6. Saad F, Gooren L. The role of testosterone in the metabolic syndrome: a review. J Steroid Biochem Mol Biol. 2009;114:40–3.PubMedCrossRefGoogle Scholar
  7. Saad F, Gooren L, Haider A, Yassin A. An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. Arch Androl J Reprod Syst. 2007;53:353–7.CrossRefGoogle Scholar
  8. Svartberg J, et al. Int J Import Res. 2008;20:378–87.CrossRefGoogle Scholar
  9. Traish AM, Guay A, Feeley R, Saad F. The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J Androl. 2009;30:10–22.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  1. 1.Department of EndocrinologyGulf Medical University & Bayer Pharma GermanyAjmanUAE
  2. 2.Hang Tuah Medical UniversitySurabayaIndonesia
  3. 3.Men’s Healthcare Scientific Affairs c/o Bayer Schering Pharma AGBerlinGermany

Personalised recommendations